·文献综述·

　　溴隐亭降糖及减重的研究进展

　　包薇萍 郑仁东 刘超

　　[摘要] 溴隐亭为多巴胺受体激动剂,近年来,研制出的溴隐亭快速释放剂型----Cycloset，已被美国食品和药品管理局(FDA)批准用于治疗T2DM。其一种作用于中枢神经系统的降糖药，可通过改善糖脂代谢，减轻IR而发挥降糖作用，为T2DM的治疗另辟蹊径。另外，本药亦可用于肥胖的治疗，并取得了显著的效果。

　　[关键词] 溴隐亭;糖尿病;糖尿病, 2型;肥胖;减重

Update on glycemic control and weight reduction with bromocriptine BAO Wei-ping, ZHENG Ren-dong, LIU Chao. Endocrine and Diabetes Center, Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China

Corresponding Author: LIU Chao, E-mail: liuchao@nfmcn.con.

　　【Summary】Recently, timed-release bromocriptine (cycloset), a sympatholytic dopamine D2 receptor agonist, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. Bromocriptine acts on the central nervous system and improves insulin sensitivity through its regulation on glycolipid metabolism, opening a new way for the treatment of T2DM. In addition, it may be used for obesity for weight reduction and the effect is good.

　　【Keywords】Bromocriptine; Diabetes mellitus, type 2; Obesity; Weight reduction